Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure ― J-SHIFT Study ―
Authors:
- 25 September 2019
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 83 (10) , 2049-2060
Abstract
Increased heart rate (HR) is an independent risk factor for cardiovascular outcomes in chronic heart failure (HF). Ivabradine, anIfinhibitor, improved outcomes in patients with HF and reduced ejection fraction (HFrEF) in the SHIFT study. We evaluated its efficacy and safety in Japanese HFrEF patients in a randomized, double-blind, placebo-controlled phase III study: the J-SHIFT study. The main objective was to confirm a hazard ratio of <1 in the primary composite endpoint of cardiovascular death or hospital admission for worsening HF.Methods and Results:Patients with NYHA functional class II-IV, left ventricular EF ≤35%, and resting HR ≥75 beats/min in sinus rhythm under optimal medical therapy received ivabradine (n=127) or placebo (n=127). Mean reduction in resting HR was significantly greater in the ivabradine group (15.2 vs. 6.1 beats/min, P<0.0001). However, symptomatic bradycardia did not occur. A total of 26 (20.5%) patients in the ivabradine group and 37 (29.1%) patients in the placebo group had the primary endpoint event (hazard ratio 0.67, 95% CI 0.40-1.11, P=0.1179) during median follow-up of 589 days. Mild phosphenes were reported in 8 (6.3%) patients in the ivabradine group and 4 (3.1%) patients in the placebo group (P=0.3760). The J-SHIFT study supported the efficacy and safety of ivabradine for Japanese HFrEF patients, in accord with the SHIFT study.Keywords
This publication has 14 references indexed in Scilit:
- Ivabradine for the Treatment of Cardiovascular DiseasesCirculation Journal, 2019
- Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)Circulation Journal, 2018
- Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure – A Randomized, Double-Blind, Placebo-Controlled Phase II Study –Circulation Journal, 2016
- Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) studyHeart and Vessels, 2013
- Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.International Heart Journal, 2013
- Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT studyClinical Research in Cardiology, 2012
- Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudyEuropean Heart Journal, 2011
- Prospective care of heart failure in Japan: lessons from CHART studiesEPMA Journal, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Predictors of mortality and morbidity in patients with chronic heart failureEuropean Heart Journal, 2005